[1]
|
D. P. Kelsen, et al.,“Adjuvant and Neoadjuvant Therapy for Gastric Cancer,” Seminars in Oncology, Vol. 23, No. 3, 1996, pp. 379-389.
|
[2]
|
D. M. Parkin, P. Pisani and J. Ferlay, “Estimates of the Worldwide Incidence of Eighteen Major Cancers in 1985,” International Journal of Cancer, Vol. 54, No. 4, 1993, pp. 594-606. doi:10.1002/ijc.2910540413
|
[3]
|
D. A. Corley and P. A. Buffler, “Oesophageal and Gastric Cardia Adenocarcinomas: Analysis of Regional Variation Using the Cancer Incidence in Five Continents Database,” International Journal of Epidemiology, Vol. 30, No. 6, 2001, pp. 1415-1425. doi:10.1093/ije/30.6.1415
|
[4]
|
B. Hermann, R. Dietrich and A. Volker, “Epidemiology of Stomach Cancer,” Springer Protocols, Vol. 472, 2008, pp. 467-477.
|
[5]
|
D. M. Parkin, F. Bray, J. Ferlay and P. Pisani, “Estimating the World Cancer Burden: Globocan 2000,” International Journal of Cancer, Vol. 94, No. 2, 2001, pp. 153-156. doi:10.1002/ijc.1440
|
[6]
|
A. Jemal, et al., “Cancer Statistics, 2008,” Cancer Journal for Clinicians, Vol. 58, No. 2, 2008, pp. 71-96.
doi:10.3322/CA.2007.0010
|
[7]
|
A. Ohtsu, “Chemotherapy for Metastatic Gastric Cancer: Past, Present, and Future,” Journal of Gastroenterology, Vol. 43, No. 4, 2008, pp. 256-264.
doi:10.1007/s00535-008-2177-6
|
[8]
|
C. S. Fuchs and R. J. Mayer, “Gastric Carcinoma,” The New England Journal of Medicine, Vol. 333, No. 1, 1995, pp. 32-41. doi:10.1056/NEJM199507063330107
|
[9]
|
Z. Liang, et al., “Analysis of EGFR,HER2, and TOP2A Gene Status and Chromosomal Polysomy in Gastric Adenocarcinoma from Chinese Patients,” BMC Cancer, Vol. 8, 2008, p. 363. doi:10.1186/1471-2407-8-363
|
[10]
|
D. A. Corley and P. A. Buffler, “Oesophageal and Gastric Cardia Adenocarcinomas: Analysis of Regional Variation Using the Cancer Incidence in Five Continents Database,” International Journal of Epidemiology, Vol. 30, No. 6, 2001, pp. 1415-1425. doi:10.1093/ije/30.6.1415
|
[11]
|
T. Takehana, et al., “Status of c-erbB-2 in Gastric Adenocarcinoma: A Comparative Study of Immunohisto-chemistry, Fluorescence in Situ Hybridization and Enzyme-Linked Immuno-Sorbent Assay,” International Journal of Cancer, Vol. 98, No. 6, 2002, pp. 833-837.
doi:10.1002/ijc.10257
|
[12]
|
L. Albarello, et al., “HER2 Testing in Gastric Cancer.” Advances in Anatomic Pathology, Vol. 18, No. 1, 2011, pp. 53-59. doi:10.1097/PAP.0b013e3182026d72
|
[13]
|
“Cetuximab Approved by FDA for Treatment of Head and Neck Squamous Cell Cancer,” Cancer Biology & Therapy, Vol. 5, No. 4, 2006, pp. 340-342.
|
[14]
|
R. M. Giusti, et al., “FDA Drug Approval Summary: Panitumumab (Vectibix),” Oncologist, Vol. 12, No. 5, 2007, pp. 577-583. doi:10.1634/theoncologist.12-5-577
|
[15]
|
M. H. Cohen, et al., “FDA Drug Approval Summary: Erlotinib (Tarceva) Tablets,” Oncologist, Vol. 10, No. 7, 2005, pp. 461-466. doi:10.1634/theoncologist.10-7-461
|
[16]
|
P. Laurent-Puig and J. Taieb, “Lessons from Tarceva in Pancreatic Cancer: Where Are We Now, and How Should Future Trials Be Designed in Pancreatic Cancer?” Current Opinion in Oncology, Vol. 20, No. 4, 2008, pp. 454-458. doi:10.1097/CCO.0b013e32830218d6
|
[17]
|
M. V. Karamouzis, et al., “Therapies Directed against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas,” Journal of the American Medical Association, Vol. 298, No. 1, 2007, pp. 70-82.
doi:10.1001/jama.298.1.70
|
[18]
|
A. Gon?alves, et al., “A Polymorphism of EGFR Extracellular Domain Is Associated with Progression Free-Survival in Metastatic Colorectal Cancer Patients Receiving Cetuximab-Based Treatment,” BMC Cancer, Vol. 8, 2008, p. 169. doi:10.1186/1471-2407-8-169
|
[19]
|
P. Lauren, “The Two Histological Main Types of Gastric Carcinoma: Diffuse and so Called Intestinal Type Carcinoma. An Attempt at a Histo-Clinical Classification,” Acta Pathol Microbiol Scand, Vol. 64, 1965, pp. 31-49.
|
[20]
|
T. Braut, et al., “Epidermal Growth Factor Receptor Protein Expression and Gene Amplification in Normal, Hyperplastic, and Cancerous Glottic Tissue: Immunohisto-chemical and Fluorescent in Situ Hybridization Study on Tissue Microarrays,” Croatian Medical Journal, Vol. 50, No. 4, 2009, pp. 370-379. doi:10.3325/cmj.2009.50.370
|
[21]
|
R. Bhargava, et al., “EGFR Gene Amplification in Breast Cancer: Correlation with Epidermal Growth Factor Receptor mRNA and Protein Expression and HER-2 Status and Absence of EGFR-Activating Mutations,” Modern Pathology, Vol. 18, No. 8, 2005, pp. 1027-1033.
doi:10.1038/modpathol.3800438
|
[22]
|
C. G. Kleer, et al., “Pathologic, Immunohistochemical, and Molecular Features of Benign and Malignant Phyllodes Tumors of the Breast,” Modern Pathology, Vol. 14, No. 3, 2008, pp. 185-190.
doi:10.1038/modpathol.3880282
|
[23]
|
T. Dragovich and C. Campen, “Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept,” Journal of Oncology, Vol. 2009, 2009, Article ID: 804108. doi:10.1155/2009/804108
|
[24]
|
E. Mammano, et al., “Epidermal Growth Factor Receptor (EGFR): Mutational and Protein Expression Analysis in Gastric Cancer,” Anticancer Research, Vol. 26, No. 5A, 2006, pp. 3547-3350.
|
[25]
|
T. Takehana, et al., “Expression of Epidermal Growth Factor Receptor in Gastric Carcinomas,” Clinical Gastroenterology and Hepatology, Vol. 1, No. 6, 2003, pp. 438-445. doi:10.1016/S1542-3565(03)00219-2
|
[26]
|
J. W. Lee, et al., “Absence of EGFR Mutation in the Kinase Domain in Common Human Cancers Besides Non-Small Cell Lung Cancer,” International Journal of Cancer, Vol. 113, No. 3, 2005, pp. 510-511.
doi:10.1002/ijc.20591
|
[27]
|
K. Mimori, et al., “The Epidermal Growth Factor Receptor Gene Sequence Is Highly Conserved in Primary Gastric Cancers,” Journal of Surgical Oncology, Vol. 93, No. 1, 2006, pp. 44-46. doi:10.1002/jso.20426
|
[28]
|
G. Galizia, et al., “Epidermal Growth Factor Receptor (EGFR) Expression Is Associated with a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery,” World Journal of Surgery, Vol. 31, No. 7, 2007, pp. 1458-1468. doi:10.1007/s00268-007-9016-4
|
[29]
|
J. G. Paez, et al., “EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy,” Science, Vol. 304, No. 5676, 2004, pp. 1497-1500.
doi:10.1126/science.1099314
|
[30]
|
H. J. Lee, et al., “Protein Overexpression and Gene Amplification of Epidermal Growth Factor Receptor in Non Small Cell Lung Carcinomas: Comparison of Four Commercially Available Antibodies by Immunohisto-chemistry and Fluorescence in Situ Hybridization Study,” Lung Cancer, Vol. 68, No. 3, 2010, pp. 375-382.
doi:10.1016/j.lungcan.2009.07.014
|
[31]
|
M. Hofmann, et al., “Assessment of a HER2 Scoring System for Gastric Cancer: Results from a Validation Study,” Histopathology, Vol. 52, No. 7, 2008, pp. 797-805. doi:10.1111/j.1365-2559.2008.03028.x
|
[32]
|
S. C. Wang and M. C. Hung, “Cytoplasmic/Nuclear Shuttling and Tumor Progression,” Annals of the New York Academy of Sciences, Vol. 1059, 2005, pp. 11-15.
doi:10.1196/annals.1339.002
|
[33]
|
S. Y. Lin, et al., “Nuclear Localization of EGF Receptor and Its Potential New Role as a Transcription Factor,” Nature Cell Biology, Vol. 3, No. 9, 2001, pp. 802-808.
doi:10.1038/ncb0901-802
|
[34]
|
H. W. Lo, et al., “Nuclear Interaction of EGFR and STAT3 in the Activation of the iNOS/NO Pathway,” Cancer Cell, Vol. 7, No. 6, 2005, pp. 575-589.
doi:10.1016/j.ccr.2005.05.007
|
[35]
|
Lo HW, et al., “EGFR Signaling Pathway in Breast Cancers: From Traditional Signal Transduction to Direct Nuclear Translocalization,” Breast Cancer Research and Treatment, Vol. 95, No. 3, 2006, pp. 211-218.
doi:10.1007/s10549-005-9011-0
|
[36]
|
J. S. de Bono and E. K. Rowinsky, “The ErbB Receptor Family: A Therapeutic Target for Cancer,” Trends in Molecular Medicine, Vol. 8, No. 4, 2002, pp. S19-S26.
doi:10.1016/S1471-4914(02)02306-7
|
[37]
|
J. P. Kallio, et al., “Membranous Location of EGFR Immunostaining Is Associated with Good Prognosis in Renal Cell Carcinoma,” British Journal of Cancer, Vol. 89, No. 7, 2003, pp. 1266-1269.
doi:10.1038/sj.bjc.6601241
|
[38]
|
C. Langner, et al., “Are Heterogenous Results of EGFR Immunoreactivity in Renal Cell Carcinoma Related to Non-Standardised Criteria for Staining Evaluation?” Journal of Clinical Pathology, Vol. 57, No. 7, 2004, pp. 773-775. doi:10.1136/jcp.2003.015743
|
[39]
|
G. C. Li, et al., “Are Biomarkers Correlated with Recurrence Patterns in Patients with Resectable Gastric Adenocarcinoma,” Molecular Biology Reports, Vol. 39, No. 1, 2012, pp. 399-405.
doi:10.1007/s11033-011-0751-0
|
[40]
|
N. E. Hynes and H. A. Lane, “ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors,” Nature Reviews Cancer, Vol. 5, No. 5, 2005, pp. 341-354.
doi:10.1038/nrc1609
|
[41]
|
V. W. Lui, J. R. Grandis, “EGFR-Mediated Cell Cycle Regulation,” Anticancer Research, Vol. 22, No. 1A, 2002, pp. 1-11.
|
[42]
|
Tumor Research Center, “The Expression of p53, PCNA, EGFR and Its Relationship to Clinicopathological Features and Prognosis of Gastric Cancer.”
http://www.tumorres.com/tumor-biol/37091.htm
|
[43]
|
Y. Maehara, et al., “Prognostic Value of p53 Protein Expression for Patients with Gastric Cancer—A Multivariate Analysis,” British Journal of Cancer, Vol. 79, No. 7-8, 1999, pp. 1255-1261.
doi:10.1038/sj.bjc.6690201
|
[44]
|
X. P. Liu, et al., “Combined Examination of p27(Kip1), p21(Waf1/Cip1) and p53 Expression Allows Precise Estimation of Prognosis in Patients with Gastric Carcinoma,” Histopathology, Vol. 39, No. 6, 2001, pp. 603-610. doi:10.1046/j.1365-2559.2001.01283.x
|
[45]
|
M. S. Al-Moundhri, et al., “The Prognostic Significance of p53, p27 kip1, p21 waf1, HER-2/Neu, and Ki67 Proteins Expression in Gastric Cancer: A Clinicopathological and Immunohistochemical Study of 121 Arab Patients,” Journal of Surgical Oncology, Vol. 91, No. 4, 2005, pp. 243-252. doi:10.1002/jso.20324
|
[46]
|
K. Motojima, et al., “Expression of p53 Protein in Gastric Carcinomas Is Not Independently Prognostic,” Surgery, Vol. 116, No. 5, 1994, pp. 890-895.
|
[47]
|
H. E. Gabbert, et al., “The Relationship of p53 Expression to the Prognosis of 418 Patients with Gastric Carcinoma,” Cancer, Vol. 76, No. 5, 1995, pp. 720-726.
doi:10.1002/1097-0142(19950901)76:5<720::AID-CNCR2820760503>3.0.CO;2-E
|
[48]
|
V. W. Lui and J. R. Grandis, “EGFR-Mediated Cell Cycle Regulation,” Anticancer Research, Vol. 22, No. 1A, 2002, pp. 1-11.
|
[49]
|
E. Tahara, “Genetic Pathways of Two Types of Gastric Cancer,” IARC Scientific Publications, Vol. 157, 2004, pp. 327-349.
|